PMID- 30271713
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220321
IS  - 2213-4220 (Print)
IS  - 2213-4239 (Electronic)
IS  - 2213-4220 (Linking)
VI  - 7
IP  - 3
DP  - 2018 Sep
TI  - Study of the effect of the herbal composition SR2004 on hemoglobin A1c, fasting 
      blood glucose, and lipids in patients with type 2 diabetes mellitus.
PG  - 248-256
LID - 10.1016/j.imr.2018.04.002 [doi]
AB  - BACKGROUND: Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized 
      by raised blood glucose levels and peripheral insulin resistance. It is an 
      increasingly prevalent global healthcare concern. Conventional treatment options 
      are limited and in this context, there is renewed interest in evaluating the 
      clinical and biological effects of traditional therapies. We assess the effect of 
      a new herbal composition SR2004 on the hemoglobin A1c (HbA1c), fasting blood 
      glucose, and lipid profiles of patients with T2DM. METHODS: This is a single 
      center, unblinded, prospective interventional study conducted in Israel. The 
      composition SR2004 includes Morus alba, Artemisia dracunculus, Urtica dioica, 
      Cinnamomum zeylanicum, and Taraxacum officinale. One hundred and nineteen 
      patients with diagnosed T2DM were enrolled and received SR2004 in addition to 
      their usual medications. HbA1c, fasting blood glucose, and lipid profiles at 12 
      weeks were compared with baseline. In addition, the tolerability and side effects 
      of SR2004 were recorded. RESULTS: One hundred and three patients completed 12 
      weeks of follow-up (87%) and were included in the results. At 12 weeks, HbA1c 
      reduced from 9.0% to 7.1% (22%; p < 0.0001), mean blood glucose decreased from 
      211 mg/dL to 133 mg/dL (37% reduction; p < 0.0001), mean total cholesterol to 
      185 mg/dL (13% reduction; p < 0.01) and mean serum triglycerides to160 mg/dL (a 
      reduction of 40% from baseline; p < 0.001). Twelve patients (12%) had no response 
      with SR2004 supplementation. In addition, of thirteen patients who took insulin 
      at baseline, five required only oral hypoglycemics and another five reduced their 
      daily insulin requirements by 30% at 12 weeks. Clinical observations included 
      improvements in vasculopathy, including reversal of established retinopathic 
      changes in two patients.No major adverse effects were observed, with minor 
      abdominal symptoms reported in sixteen patients (16%). CONCLUSION: SR2004 
      supplementation significantly reduced HbA1c, blood glucose, and lipids with good 
      tolerability and no observed adverse interactions with conventional medications. 
      Some interesting findings relating to the reversal of microvascular phenomena 
      warrant further research to elucidate the mechanisms of action of this novel 
      composition.
FAU - Chatterji, Sumit
AU  - Chatterji S
AD  - Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
FAU - Fogel, Dov
AU  - Fogel D
AD  - D.S. Polyclinic, Givat Shmuel, Israel.
LA  - eng
PT  - Journal Article
DEP - 20180430
PL  - Netherlands
TA  - Integr Med Res
JT  - Integrative medicine research
JID - 101612707
PMC - PMC6160498
OTO - NOTNLM
OT  - Glucose
OT  - Herbal
OT  - Lipids
OT  - Retinopathy
OT  - Type 2 diabetes mellitus
EDAT- 2018/10/03 06:00
MHDA- 2018/10/03 06:01
PMCR- 2018/04/30
CRDT- 2018/10/02 06:00
PHST- 2018/01/24 00:00 [received]
PHST- 2018/03/23 00:00 [revised]
PHST- 2018/04/05 00:00 [accepted]
PHST- 2018/10/02 06:00 [entrez]
PHST- 2018/10/03 06:00 [pubmed]
PHST- 2018/10/03 06:01 [medline]
PHST- 2018/04/30 00:00 [pmc-release]
AID - S2213-4220(18)30026-X [pii]
AID - 10.1016/j.imr.2018.04.002 [doi]
PST - ppublish
SO  - Integr Med Res. 2018 Sep;7(3):248-256. doi: 10.1016/j.imr.2018.04.002. Epub 2018 
      Apr 30.